NFKB1 and Miyoshi myopathy: Notwithstanding, the preclinical safety and on-target-specific pharmacology of DTP3 we report here, together with the potent and cancer-selective therapeutic efficacy previously demonstrated in MM cells from patients and mouse MM xenograft models, and the recently published encouraging clinical results in MM patients [28], demonstrate that the safe inhibition of the NF-κB survival pathway is clinically achievable and capable of producing the desired therapeutic effects, with profound implications in oncology, beyond MM.